Aortic Branch Aneurysms and Vascular Risk in Patients With Marfan Syndrome.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
22 06 2021
Historique:
received: 01 03 2021
revised: 09 04 2021
accepted: 13 04 2021
entrez: 18 6 2021
pubmed: 19 6 2021
medline: 1 12 2021
Statut: ppublish

Résumé

Aortic branch aneurysms are not included in the diagnostic criteria for Marfan syndrome (MFS); however, their prevalence and eventual prognostic significance are unknown. The goal of this study was to assess the prevalence of aortic branch aneurysms in MFS and their relationship with aortic prognosis. MFS patients with a pathogenic FBN1 genetic variant and at least one magnetic resonance or computed tomography angiography study assessing aortic branches were included. Aortic events and those related to aneurysm complications were recorded during follow-up. A total of 104 aneurysms were detected in 50 (26.7%) of the 187 patients with MFS (mean age 37.9 ± 14.4 years; 54% male) included in this study, with the iliac artery being the most common location (45 aneurysms). Thirty-one patients (62%) had >1 peripheral aneurysm, and surgery was performed in 5 (4.8%). Patients with aneurysms were older (41.9 ± 12.7 years vs. 36.7 ± 14.8 years; p = 0.040) and had more dilated aortic root (42.2 ± 6.4 mm vs. 38.8 ± 8.0 mm; p = 0.044) and dyslipidemia (31.0% vs. 9.7%; p = 0.001). In a subgroup of 95 patients with no previous aortic surgery or dissection followed up for 3.3 ± 2.6 years, the presence of arterial aneurysms was associated with a greater need for aortic surgery (hazard ratio: 3.4; 95% confidence interval: 1.1 to 10.3; p = 0.028) in a multivariable Cox analysis adjusted for age and aortic diameter. Aortic branch aneurysms are present in one-quarter of patients with MFS and are related to age and aortic dilation, and they independently predict the need for aortic surgery. The systematic use of whole-body vascular assessment is recommended to identify other sites of vascular involvement at risk for complications and to define the subgroup of patients with more aggressive aortic disease.

Sections du résumé

BACKGROUND
Aortic branch aneurysms are not included in the diagnostic criteria for Marfan syndrome (MFS); however, their prevalence and eventual prognostic significance are unknown.
OBJECTIVES
The goal of this study was to assess the prevalence of aortic branch aneurysms in MFS and their relationship with aortic prognosis.
METHODS
MFS patients with a pathogenic FBN1 genetic variant and at least one magnetic resonance or computed tomography angiography study assessing aortic branches were included. Aortic events and those related to aneurysm complications were recorded during follow-up.
RESULTS
A total of 104 aneurysms were detected in 50 (26.7%) of the 187 patients with MFS (mean age 37.9 ± 14.4 years; 54% male) included in this study, with the iliac artery being the most common location (45 aneurysms). Thirty-one patients (62%) had >1 peripheral aneurysm, and surgery was performed in 5 (4.8%). Patients with aneurysms were older (41.9 ± 12.7 years vs. 36.7 ± 14.8 years; p = 0.040) and had more dilated aortic root (42.2 ± 6.4 mm vs. 38.8 ± 8.0 mm; p = 0.044) and dyslipidemia (31.0% vs. 9.7%; p = 0.001). In a subgroup of 95 patients with no previous aortic surgery or dissection followed up for 3.3 ± 2.6 years, the presence of arterial aneurysms was associated with a greater need for aortic surgery (hazard ratio: 3.4; 95% confidence interval: 1.1 to 10.3; p = 0.028) in a multivariable Cox analysis adjusted for age and aortic diameter.
CONCLUSIONS
Aortic branch aneurysms are present in one-quarter of patients with MFS and are related to age and aortic dilation, and they independently predict the need for aortic surgery. The systematic use of whole-body vascular assessment is recommended to identify other sites of vascular involvement at risk for complications and to define the subgroup of patients with more aggressive aortic disease.

Identifiants

pubmed: 34140103
pii: S0735-1097(21)04825-7
doi: 10.1016/j.jacc.2021.04.054
pmc: PMC8091372
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3005-3012

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This study was funded by Instituto de Salud Carlos III through the project PI17/00381, La Marató de TV3 (project no. 20151330). Dr. Guala has received funding from the European Union Seventh Framework Programme FP7/People (grant agreement no. 267128) and from the Spanish Ministry of Science, Innovation and Universities (IJC2018-037349-I). Dr. La Mura was supported by a research grant provided by the Cardiopath PhD programme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Angela Lopez-Sainz (A)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.

Laia Mila (L)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERCV Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Jose Rodriguez-Palomares (J)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERCV Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Javier Limeres (J)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERCV Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Chiara Granato (C)

Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.

Lucia La Mura (L)

Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Ana Sabaté (A)

Department of Pediatric Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.

Andrea Guala (A)

Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERCV Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Laura Gutiérrez (L)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERCV Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Laura Galian-Gay (L)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERCV Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Augusto Sao-Aviles (A)

Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.

Sergi Bellmunt (S)

Department of Angiology, Vascular and Endovascular Surgery, Vall d'Hebron Hospital Universitari, Barcelona, Spain.

Rafael Rodriguez (R)

Department of Cardiac Surgery, Vall d'Hebron Hospital Universitari, Barcelona, Spain.

Hug Cuellar-Calabria (H)

Department of Radiology, IDI (Institut de Diagnòstic per la Imatge), Vall d'Hebron Hospital Universitari, Barcelona, Spain.

Albert Roque (A)

Department of Radiology, IDI (Institut de Diagnòstic per la Imatge), Vall d'Hebron Hospital Universitari, Barcelona, Spain.

Ignacio Ferreira-González (I)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERESP Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain.

Artur Evangelista (A)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERCV Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: arturevangelistamasip@gmail.com.

Gisela Teixido-Tura (G)

Department of Cardiology, Vall d'Hebron Hospital Universitari, Barcelona, Spain; Grupo de Enfermedades Cardiovasculares, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBERCV Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: gteixido@vhebron.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH